Book contents
- Movement Disorders and Inherited Metabolic Disorders
- Movement Disorders and Inherited Metabolic Disorders
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Acknowledgments
- Section I General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Section II A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Chapter 12 Disorders of Amino Acid Metabolism: Amino Acid Disorders, Organic Acidurias, and Urea Cycle Disorders with Movement Disorders
- Chapter 13 Disorders of Energy Metabolism: GLUT1 Deficiency Syndrome and Movement Disorders
- Chapter 14 Lysosomal Storage Disorders: Niemann–Pick Disease Type C and Movement Disorders
- Chapter 15 Lysosomal Storage Disorders: Neuronal Ceroid Lipofuscinoses and Movement Disorders
- Chapter 16 Syndromes of Neurodegeneration with Brain Iron Accumulation
- Chapter 17 Metal Storage Disorders: Inherited Disorders of Copper and Manganese Metabolism and Movement Disorders
- Chapter 18 Metal Storage Disorders: Primary Familial Brain Calcification and Movement Disorders
- Chapter 19 Disorders of Glycosylation and Movement Disorders
- Chapter 20 Disorders of Post-Translational Modifications/Degradation: Autophagy and Movement Disorders
- Chapter 21 Neurotransmitter Disorders: Disorders of Dopamine Metabolism and Movement Disorders
- Chapter 22 Neurotransmitter Disorders: DNAJC12-Deficient Hyperphenylalaninemia – An Emerging Neurotransmitter Disorder
- Chapter 23 Neurotransmitter Disorders: Disorders of GABA Metabolism and Movement Disorders
- Chapter 24 Vitamin-Responsive Disorders: Ataxia with Vitamin E Deficiency and Movement Disorders
- Chapter 25 Vitamin-Responsive Disorders: Biotin–Thiamine-Responsive Basal Ganglia Disease and Movement Disorders
- Chapter 26 Disorders of Cholesterol Metabolism: Cerebrotendinous Xanthomatosis and Movement Disorders
- Chapter 27 Purine Metabolism Defects: The Movement Disorder of Lesch–Nyhan Disease
- Chapter 28 Disorders of Creatine Metabolism: Creatine Deficiency Syndromes and Movement Disorders
- Chapter 29 Hereditary Spastic Paraplegia-Related Inborn Errors of Metabolism
- Section III Conclusions and Future Directions
- Appendix: Video Captions
- Index
- References
Chapter 12 - Disorders of Amino Acid Metabolism: Amino Acid Disorders, Organic Acidurias, and Urea Cycle Disorders with Movement Disorders
from Section II - A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders
Published online by Cambridge University Press: 24 September 2020
Book contents
- Movement Disorders and Inherited Metabolic Disorders
- Movement Disorders and Inherited Metabolic Disorders
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Acknowledgments
- Section I General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Section II A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Chapter 12 Disorders of Amino Acid Metabolism: Amino Acid Disorders, Organic Acidurias, and Urea Cycle Disorders with Movement Disorders
- Chapter 13 Disorders of Energy Metabolism: GLUT1 Deficiency Syndrome and Movement Disorders
- Chapter 14 Lysosomal Storage Disorders: Niemann–Pick Disease Type C and Movement Disorders
- Chapter 15 Lysosomal Storage Disorders: Neuronal Ceroid Lipofuscinoses and Movement Disorders
- Chapter 16 Syndromes of Neurodegeneration with Brain Iron Accumulation
- Chapter 17 Metal Storage Disorders: Inherited Disorders of Copper and Manganese Metabolism and Movement Disorders
- Chapter 18 Metal Storage Disorders: Primary Familial Brain Calcification and Movement Disorders
- Chapter 19 Disorders of Glycosylation and Movement Disorders
- Chapter 20 Disorders of Post-Translational Modifications/Degradation: Autophagy and Movement Disorders
- Chapter 21 Neurotransmitter Disorders: Disorders of Dopamine Metabolism and Movement Disorders
- Chapter 22 Neurotransmitter Disorders: DNAJC12-Deficient Hyperphenylalaninemia – An Emerging Neurotransmitter Disorder
- Chapter 23 Neurotransmitter Disorders: Disorders of GABA Metabolism and Movement Disorders
- Chapter 24 Vitamin-Responsive Disorders: Ataxia with Vitamin E Deficiency and Movement Disorders
- Chapter 25 Vitamin-Responsive Disorders: Biotin–Thiamine-Responsive Basal Ganglia Disease and Movement Disorders
- Chapter 26 Disorders of Cholesterol Metabolism: Cerebrotendinous Xanthomatosis and Movement Disorders
- Chapter 27 Purine Metabolism Defects: The Movement Disorder of Lesch–Nyhan Disease
- Chapter 28 Disorders of Creatine Metabolism: Creatine Deficiency Syndromes and Movement Disorders
- Chapter 29 Hereditary Spastic Paraplegia-Related Inborn Errors of Metabolism
- Section III Conclusions and Future Directions
- Appendix: Video Captions
- Index
- References
Summary
Humans depend on dietary proteins as a source of amino acids; they are the metabolic basis of all functional and structural proteins in the body. Some amino acids – termed essential – cannot be synthesized by the human body, such L-isoleucine and L-phenylalanine. Renal conservation of amino acids is extremely effective, with clearance values mostly below 1%. Stool nitrogen losses are about 1 g per day and are mostly of bacterial origin. In contrast to glucose and fatty acids, amino acids taken in excess of requirement cannot be stored but their carbon backbones are used for energy production.
- Type
- Chapter
- Information
- Movement Disorders and Inherited Metabolic DisordersRecognition, Understanding, Improving Outcomes, pp. 171 - 182Publisher: Cambridge University PressPrint publication year: 2020
References
Kolker, S, Garcia-Cazorla, A, Valayannopoulos, V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: The initial presentation. J Inherit Metab Dis. 2015;38(6):1041–57.Google ScholarPubMed
Kolker, S, Valayannopoulos, V, Burlina, AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: The evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059–74.Google Scholar
Kolker, S, Sauer, SW, Hoffmann, GF, et al. Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism. J Inherit Metab Dis. 2008;31(2):194–204.Google Scholar
Baumgartner, MR, Horster, F, Dionisi-Vici, C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.Google Scholar
Boy, N, Muhlhausen, C, Maier, EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: Second revision. J Inherit Metab Dis. 2017;40(1):75–101.CrossRefGoogle ScholarPubMed
Haberle, J, Boddaert, N, Burlina, A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.Google Scholar
van Spronsen, FJ, van Wegberg, AM, Ahring, K, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.Google ScholarPubMed
Niemi, AK, Kim, IK, Krueger, CE, et al. Treatment of methylmalonic acidemia by liver or combined liver–kidney transplantation. J Pediatr. 2015;166(6):1455–61 e1.CrossRefGoogle ScholarPubMed
Lindner, M, Gramer, G, Haege, G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases: Report of 10 years from south-west Germany. Orphanet J Rare Dis. 2011;6:44.CrossRefGoogle ScholarPubMed
Pietz, J, Kreis, R, Rupp, A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103(8):1169–78.Google Scholar
Burgard, P, Schmidt, E, Rupp, A, Schneider, W, Bremer, HJ. Intellectual development of the patients of the German collaborative study of children treated for phenylketonuria. Eur J Pediatr. 1996;155 Suppl 1:S33-8.Google Scholar
van Wegberg, AMJ, MacDonald, A, Ahring, K, et al. The complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.Google Scholar
Koch, R, Hanley, W, Levy, H, et al. The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics. 2003; 112 (6 Pt 2): 1523–9.Google Scholar
Muntau, AC, Roschinger, W, Habich, M, et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med. 2002;347(26):2122–32.Google Scholar
Kolker, S, Burgard, P, Sauer, SW, Okun, JG. Current concepts in organic acidurias: Understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis. 2013;36(4):635–44.CrossRefGoogle ScholarPubMed
Morath, MA, Okun, JG, Muller, IB, et al. Neurodegeneration and chronic renal failure in methylmalonic aciduria: A pathophysiological approach. J Inherit Metab Dis. 2008;31(1):35–43.CrossRefGoogle ScholarPubMed
Schwab, MA, Sauer, SW, Okun, JG, et al. Secondary mitochondrial dysfunction in propionic aciduria: A pathogenic role for endogenous mitochondrial toxins. Biochem J. 2006;398(1):107–12.CrossRefGoogle ScholarPubMed
Luciani, A, Schumann, A, Berquez, M, et al. Impaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency. Nat Commun. 2020;11(1):970.Google ScholarPubMed
Chandler, RJ, Zerfas, PM, Shanske, S, et al. Mitochondrial dysfunction in MUT methylmalonic acidemia. FASEB J. 2009;23(4):1252–61.Google Scholar
de Keyzer, Y, Valayannopoulos, V, Benoist, JF, et al. Multiple OXPHOS deficiency in the liver, kidney, heart, and skeletal muscle of patients with methylmalonic aciduria and propionic aciduria. Pediatr Res. 2009;66(1):91–5.Google Scholar
Horster, F, Baumgartner, MR, Viardot, C, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut–, cblA, cblB). Pediatr Res. 2007;62(2):225–30.CrossRefGoogle ScholarPubMed
Baker, EH, Sloan, JL, Hauser, NS, et al. MRI characteristics of globus pallidus infarcts in isolated methylmalonic acidemia. AJNR Am J Neuroradiol. 2015;36(1):194–201.Google Scholar
Valayannopoulos, V, Baruteau, J, Delgado, MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk–benefit profile: A retrospective observational study. Orphanet J Rare Dis. 2016;11:32.Google Scholar
Sauer, SW, Okun, JG, Fricker, G, et al. Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood–brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. J Neurochem. 2006;97(3):899–910.Google Scholar
Sauer, SW, Okun, JG, Schwab, MA, et al. Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency: A role for glutaryl-coenzyme A. J Biol Chem. 2005;280(23):21830–6.Google Scholar
Strauss, KA, Donnelly, P, Wintermark, M. Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency. Brain. 2010;133(Pt 1):76–92.Google Scholar
Tan, M, Peng, C, Anderson, KA, et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014;19(4):605–17.Google Scholar
Harting, I, Neumaier-Probst, E, Seitz, A, et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain. 2009;132(Pt 7):1764–82.Google Scholar
Funk, CB, Prasad, AN, Frosk, P et al. Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort. Brain. 2005;128(Pt 4):711–22.Google Scholar
Gitiaux, C, Roze, E, Kinugawa, K, et al. Spectrum of movement disorders associated with glutaric aciduria type 1: A study of 16 patients. Mov Disord. 2008;23(16):2392–7.Google Scholar
Bjugstad, KB, Goodman, SI, Freed, CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. J Pediatr. 2000;137(5):681–6.CrossRefGoogle ScholarPubMed
Boy, N, Mengler, K, Thimm, E, et al. Newborn screening: A disease-changing intervention for glutaric aciduria type 1. Ann Neurol. 2018;83(5):970–9.Google Scholar
Sauer, SW, Opp, S, Hoffmann, GF, et al. Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I. Brain. 2011;134(Pt 1):157–70.CrossRefGoogle Scholar
Topcu, M, Jobard, F, Halliez, S, et al. L-2-Hydroxyglutaric aciduria: Identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum Mol Genet. 2004;13(22):2803–11.Google Scholar
Van Schaftingen, E, Rzem, R, Marbaix, A, et al. Metabolite proofreading, a neglected aspect of intermediary metabolism. J Inherit Metab Dis. 2013;36(3):427–34.CrossRefGoogle ScholarPubMed
Steenweg, ME, Jakobs, C, Errami, A, et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: A genotype–phenotype study. Hum Mutat. 2010;31(4):380–90.Google Scholar
Moroni, I, Bugiani, M, D’Incerti, L, et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: A predisposing condition? Neurology. 2004;62(10):1882–4.Google Scholar
Patay, Z, Mills, JC, Lobel, U, et al. Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data. AJNR Am J Neuroradiol. 2012;33(5):940–3.Google Scholar
Burgard, P, Kolker, S, Haege, G, Lindner, M, Hoffmann, GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders: Review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis. 2016;39(2):219–29.Google Scholar
Martinelli, D, Diodato, D, Ponzi, E, et al. The hyperornithinemia–hyperammonemia–homocitrullinuria syndrome. Orphanet J Rare Dis. 2015;10:29.Google Scholar
An, D, Schneller, JL, Frassetto, A, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548–58.Google Scholar